کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8673983 | 1578852 | 2017 | 15 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Hypoactive Sexual Desire Disorder
ترجمه فارسی عنوان
اختلال میل جنسی سوزنده
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
ACCMPOAMSHNAccVTAInternational Statistical Classification of Diseases and Related Health Problems, 10th revisionICD-10HSDDFDAGnRHArcNCPUDSMPFCcaudate-putamen - Caudate-PutamenVentral pallidum - pallidum درشتHypoactive Sexual Desire Disorder - اختلال میل جنسی سوزندهoxytocin - اکسیتوسینOlfactory tubercle - تومور رحمیDopamine - دوپامینDiagnostic and Statistical Manual of Mental Disorders - راهنمای تشخیصی و آماری اختلالهای روانیCBT - رفتار درمانی شناختی Cognitive Behavior Therapy - رفتار درمانی شناختی Food and Drug Administration - سازمان غذا و داروadverse event - عارضه جانبی یا عوارض جانبیPituitary - غدهٔ زیرمغزی یا هیپوفیزanterior cingulate cortex - قشر سینگولیت قدامی، کورتکس سینگولیت قدامیpiriform cortex - قشر پریکومmedial preoptic area - منطقه پیشوپتیک مدیاventral tegmental area - ناحیه تگمنتوم شکمیnorepinephrine - نوراپی نفرینNucleus accumbens - هسته accumbensarcuate nucleus of the hypothalamus - هسته قوس هیپوتالاموسGonadotropin-releasing hormone - هورمون آزاد کننده گنادوتروپینMelanocyte-stimulating hormone - هورمون تحریک کننده ملانوستیPit - گودالcannabinoid type 1 receptor - گیرنده نوع 1 کانابینوئیدdelta opioid receptors - گیرنده های اپتیک دلتاmu Opioid receptors - گیرنده های اپیدمی مو
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
کاردیولوژی و پزشکی قلب و عروق
چکیده انگلیسی
The objective of the International Society for the Study of Women's Sexual Health expert consensus panel was to develop a concise, clinically relevant, evidence-based review of the epidemiology, physiology, pathogenesis, diagnosis, and treatment of hypoactive sexual desire disorder (HSDD), a sexual dysfunction affecting approximately 10% of adult women. Etiologic factors include conditions or drugs that decrease brain dopamine, melanocortin, oxytocin, and norepinephrine levels and augment brain serotonin, endocannabinoid, prolactin, and opioid levels. Symptoms include lack or loss of motivation to participate in sexual activity due to absent or decreased spontaneous desire, sexual desire in response to erotic cues or stimulation, or ability to maintain desire or interest through sexual activity for at least 6 months, with accompanying distress. Treatment follows a biopsychosocial model and is guided by history and assessment of symptoms. Sex therapy has been the standard treatment, although there is a paucity of studies assessing efficacy, except for mindfulness-based cognitive behavior therapy. Bupropion and buspirone may be considered off-label treatments for HSDD, despite limited safety and efficacy data. Menopausal women with HSDD may benefit from off-label testosterone treatment, as evidenced by multiple clinical trials reporting some efficacy and short-term safety. Currently, flibanserin is the only Food and Drug Administration-approved medication to treat premenopausal women with generalized acquired HSDD. Based on existing data, we hypothesize that all these therapies alter central inhibitory and excitatory pathways. In conclusion, HSDD significantly affects quality of life in women and can effectively be managed by health care providers with appropriate assessments and individualized treatments.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Mayo Clinic Proceedings - Volume 92, Issue 1, January 2017, Pages 114-128
Journal: Mayo Clinic Proceedings - Volume 92, Issue 1, January 2017, Pages 114-128
نویسندگان
Irwin MD, Noel N. PhD, Anita H. MD, Leonard R. PhD, Annamaria MD, PhD, Sharon J. MD, James PhD, James A. MD, Sheryl A. PhD, Cindy PhD, Stephen M. MD, Kim PhD, Roisin MBBS,